Answers are grounded in this paper and cite their sources.
Patients with a severe and moderate form of hemophilia A have traditionally been prescribed standard prevention with a coagulation factor VIII (FVIII), the goal of which is to achieve zero bleedings per year and a remaining activity of FVIII no fewer than 1 %. The standard approach does not allow achieving these goals in many patients due to a variety of factors: age of the patient, lifestyle, level of physical activity, condition of joints, muscle tone, patient compliance, individual pharmacokinetic (PK) response to FVIII administration. The target remaining activity of FVIII may be 2, 3 or even 5 % depending on the level of physical activity. Nowadays an individualized approach to the treatment of patients with severe hemophilia A based on the patient's PK profile is actively being explored and implemented in clinical practice. Individualization of prevention in patients with severe hemophilia is a real need for the physician and patient. There is a high variability in the values of the half-life period of FVIII in different patients. It is necessary to monitor the duration of the time period when the remaining activity of FVIII is less than 1 %, i.e., the period which is directly linked to the risk of spontaneous hemorrhage. For the patients getting treatment of Octocog alfa there has been developed the software (SW) myPKFiT* on the basis of web application which allows to simulate a dosage regimen taking into account the patient's PC profile based on the determination of FVIII activity in 2 blood sample. The SW allows changing (increase) the target level of the remaining activity of FVIII considering the lifestyle and the level of physical activity of the patient. The ability of SW allows the patient to demonstrate the activity of FVIII at various doses and intervals of drugs, as well as identify the risks that arise when a drug is missed. Therefore, myPKFiT solves an important task of the individualized approach to selection and correction of therapy, improves the collaboration and mutual understanding between the physician and the patient, up regulates of the patient adherence to the therapy and achieves optimal results.
No takes yet. Share an insight, caveat, or question.
Zozulya et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: